ST景峰: 2025年半年度业绩预告

Performance Forecast - The company expects a net loss of between 30 million to 45 million yuan for the first half of 2025, compared to a loss of 33.05 million yuan in the same period last year [1] - The expected loss after deducting non-recurring gains and losses is projected to be between 27 million to 40.5 million yuan, compared to a loss of 26.5 million yuan in the previous year [1] - The estimated basic earnings per share are expected to be a loss of 0.0340 to 0.0510 yuan per share, compared to a loss of 0.0376 yuan per share last year [1] - The anticipated operating revenue is between 150 million to 190 million yuan, down from 202.58 million yuan in the same period last year [1] Reasons for Performance Change - The decline in sales revenue of the company's core products is attributed to stricter medical insurance cost control measures, which have negatively impacted overall profitability [1] Financial Reporting and Audit - The financial data in the performance forecast has not been audited by an accounting firm [1] - The company has been in a pre-restructuring process, and there is uncertainty regarding its ability to enter the restructuring process [2] - The 2024 annual audit report from the accounting firm highlighted significant uncertainties regarding the company's ability to continue as a going concern [2]